Table 5.
Heart failure-related rehospitalization vs. no rehospitalization in relation to 180-day all-cause death
| Risk factor | Multivariable
|
||
|---|---|---|---|
| HR (95% CI) | SE | P-value | |
| HF rehospitalization vs. no HF rehospitalization | 2.04 (1.56–2.67) | 0.137 | <0.001 |
| ACEI or ARB use | 0.68 (0.56–0.82) | 0.097 | 0.001 |
| Respiratory rate < 20, per 5 breaths/min | 1.10 (0.96–1.25) | 0.014 | 0.174 |
| Respiratory rate ≥20, per 5 breaths/min | 1.20 (0.88–1.64) | 0.032 | 0.249 |
| Systolic BP <130 mmHg, per 5 mmHg | 0.94 (0.90–0.98) | 0.005 | 0.003 |
| Systolic BP ≥130 mmHg, per 5 mmHg | 0.99 (0.95–1.04) | 0.005 | 0.801 |
| Chronic loop diuretic use | 1.66 (1.31–2.09) | 0.119 | <0.001 |
| Hospitalization in last year | 1.22 (1.02–1.46) | 0.093 | 0.032 |
| Log of creatinine (mg), per doubling | 1.45 (1.22–1.72) | 0.087 | <0.001 |
| Asia Pacific vs. North America | 1.12 (0.89–1.41) | 0.118 | 0.339 |
| Central Europe vs. North America | 0.67 (0.49–0.96) | 0.169 | 0.026 |
| Latin America vs. North America | 1.55 (1.16–2.07) | 0.148 | 0.003 |
| Western Europe vs. North America | 1.23 (0.88–1.73) | 0.172 | 0.221 |
| History of cerebrovascular disease | 1.50 (1.19–1.89) | 0.118 | 0.001 |
| Digoxin use | 1.24 (1.03–1.50) | 0.097 | 0.027 |
| History of ischaemic heart disease | 1.19 (0.99–1.44) | 0.096 | 0.067 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; HF, heart failure; HR, hazard ratio; SE, standard error.